Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2024 / Oct / Victor Ambros and Gary Ruvkun share 2024 Nobel Prize for Physiology or Medicine
Genetics and epigenetics Profession Molecular Pathology

Victor Ambros and Gary Ruvkun share 2024 Nobel Prize for Physiology or Medicine

The Nobel Prize for Medicine has again been awarded jointly, this time for miRNA discovery and its role in gene regulation

By Rob Coker 10/09/2024 News 1 min read

Share

The 2024 Nobel Prize for Physiology or Medicine has been jointly awarded to Victor Ambros, now at the University of Massachusetts Medical School, and Gary Ruvkun of Harvard Medical School for the discovery of microRNA (miRNA) for use in gene regulation.

Credit: Adam Baker, CC BY 2.0 <https://creativecommons.org/licenses/by/2.0>, via Wikimedia Commons

The Nobel Assembly of Sweden’s Karolinska Institutet medical university made the announcement today, stating that the “surprising discovery revealed an entirely new dimension to gene regulation. MicroRNAs are proving to be fundamentally important for how organisms develop and function.”

Ambros was part of the team first discovered miRNAs in 1993 alongside Rosalind Lee, and Rhonda Feinbaum. While studying the development of the C. elegans roundworm, they identified lin-4 – a small RNA molecule – as a key regulator of developmental timing. Seven years later, Ruvkun was part of the team that discovered a second miRNA, let-7, which led to the realization that miRNAs are fundamental across species, including humans.

MiRNAs work by binding to complementary sequences in messenger RNAs (mRNAs), leading to the degradation or inhibition of the mRNA, thereby controlling protein synthesis.

Since their discovery, miRNAs have been found to be involved in a wide range of biological processes, including cell proliferation, differentiation, and apoptosis. They are also implicated in various diseases, especially cancer, cardiovascular disorders, and neurodegenerative diseases. miRNAs can function as oncogenes or tumor suppressors, depending on their target genes. This has spurred research into using miRNAs as biomarkers for disease diagnosis and prognosis, as well as potential therapeutic targets.

Today, miRNA-based therapies are being explored for conditions such as cancer and viral infections, with some candidates in clinical trials. Their ability to fine-tune gene expression continues to make miRNAs an exciting focus for therapeutic innovation.

The worlds of industry and science continue to anticipate the possibilities of miRNA technology now that it has developed and been elevated to the status of other Nobel Prize winning discoveries. The 2023 Nobel Prize was also jointly awarded to pharmaceutical scientists Katalin Karikó and Drew Weissman for the development of mRNA vaccines against COVID-19.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Rob Coker

Following a Bachelor’s degree in English Literature and a Master’s in Creative Writing, I entered the world of publishing as a proofreader, working my way up to editor. The career so far has taken me to some amazing places, and I’m excited to see where I can go with Conexaint and The Medicine Maker.

More Articles by Rob Coker

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Breathing New Life into Diagnostics
Genetics and epigenetics
Breathing New Life into Diagnostics

January 22, 2024

6 min read

Jonathan Edgeworth on how metagenomics could transform testing for respiratory infections

Molecular Spectacular
Genetics and epigenetics
Molecular Spectacular

January 8, 2024

1 min read

A look at last year’s most interesting molecular pathology stories

Redefining Diagnostic Reference Standards
Genetics and epigenetics
Redefining Diagnostic Reference Standards

January 3, 2022

1 min read

Find out what Horizon Discovery’s diagnostic reference standards can do for your workflow

Defining the Next Generation of NGS
Genetics and epigenetics
Defining the Next Generation of NGS

December 31, 2021

1 min read

Overcoming challenges of the typical NGS workflow with the Ion Torrent™ Genexus™ System

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.